• capital expenditure towards procurement of equipment and machinery for our Company.• investment in our Material Subsidiary, Bioneeds India Private Limited for capital expenditure towards procurement of equipment and machinery.• investment in our Material Subsidiary, Bioneeds India Private Limited for repayment/pre-payment, in part or full of certain borrowings of our Subsidiary, Bioneeds India Private Limited.• funding organic growth of our Company, our Material Subsidiary, Bioneeds India Private Limited and Health Data Specialists (Holdings) Limited through marketing and promotional activities, updation of technology and adoption of modern digital solutions in our workflows to enhance the efficiency and quality assurance of our operating processes and data management.• General corporate purposes.
...
us stages of the drug development value chain ranging from non-clinical and preclinicaldevelopment and testing to early phase clinical pharmacology, bioavailability and bioequivalence studiesand early to late phase clinical trials for different modalities of drugs including novel chemical entities, novelbiological entities, generics and biosimilars besides medical devices. Our services include: (i) early phase and latephase clinical trials (“Clinical Trials”); (ii) Healthy volunteer studies (“HVS”) which includes bioavailabilitystudies and bioequivalence studies; (iii) pre-clinical trials and non-clinical testing (“Pre-Clinical”); and (iv)biopharma services which includes non-clinical analysis and clinical bioanalysis of large molecules (“BiopharmaServices”). We are present across the key global markets including North America, Europe and Asia, includingIndia. Read More
Posted on Dec 22nd
Mallikarjun Kharge on rail ticket prices hike: Modi govt leaving no opportunity to loot public
Posted on Dec 22nd
Nifty December 2025 futures close at a premium of 29.00 points over spot closing
Posted on Dec 22nd
Nanta Tech coming with IPO to raise Rs 31.81 crore
Posted on Dec 22nd
Currency futures for December expiry trade stronger with 1.83% decrease in OI
The issue size of Veeda Clinical Research Ltd. IPO is ₹0.00 - 0.00 crore.
The Veeda Clinical Research Ltd. IPO opens for subscription on and closes on .
The price range of Veeda Clinical Research Ltd. IPO is ₹0.00 to ₹0.00.
The lot size of Veeda Clinical Research Ltd. IPO is shares.
The registrar of Veeda Clinical Research Ltd. IPO is .
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.